SecSonar.com

Illumina, Inc. (ILMN)

Illumina, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Illumina, Inc. (ILMN) is a Medical - Diagnostics & Research company based in US with a market capitalization of $25B. Revenue declined 0.8% year-over-year and the company generated $931M in free cash flow. This page tracks ILMN's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 8.97K employees · IPO Jul 28, 2000

Valuation

Valuation & price

$142.54 · as of May 17, 2026 · -24.5% vs 52w high

26.2

P/E ratio

Latest-FY diluted EPS

9.17

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$189$140$91.00Jul 25Dec 25Jul 26Jul 7, 25$97.15Jul 9, 25$97.44Jul 11, 25$99.25Jul 15, 25$97.15Jul 17, 25$97.93Jul 21, 25$94.80Jul 23, 25$104.61Jul 25, 25$109.30Jul 29, 25$108.71Jul 31, 25$102.71Aug 4, 25$98.44Aug 6, 25$94.43Aug 11, 25$94.78Aug 13, 25$101.11Aug 15, 25$100.11Aug 19, 25$101.60Aug 21, 25$99.29Aug 25, 25$99.66Aug 27, 25$99.54Aug 29, 25$99.96Sep 3, 25$96.07Sep 5, 25$98.93Sep 9, 25$98.22Sep 11, 25$99.31Sep 16, 25$101.48Sep 18, 25$103.03Sep 22, 25$101.49Sep 24, 25$94.41Sep 26, 25$91.69Sep 30, 25$94.97Oct 2, 25$99.30Oct 6, 25$101.02Oct 8, 25$97.78Oct 10, 25$93.86Oct 14, 25$91.00Oct 16, 25$95.91Oct 21, 25$98.96Oct 23, 25$99.97Oct 27, 25$100.35Oct 29, 25$95.03Oct 31, 25$123.54Nov 4, 25$116.86Nov 6, 25$121.11Nov 10, 25$121.72Nov 12, 25$121.98Nov 14, 25$120.67Nov 18, 25$121.97Nov 20, 25$119.26Nov 25, 25$129.64Nov 28, 25$131.45Dec 2, 25$127.55Dec 4, 25$128.03Dec 8, 25$127.25Dec 10, 25$134.91Dec 12, 25$134.87Dec 16, 25$131.56Dec 18, 25$130.51Dec 22, 25$137.60Dec 24, 25$135.32Dec 29, 25$134.48Jan 2, 26$134.35Jan 6, 26$147.11Jan 8, 26$145.83Jan 12, 26$145.55Jan 14, 26$143.97Jan 16, 26$141.65Jan 21, 26$152.48Jan 23, 26$150.28Jan 27, 26$152.09Jan 29, 26$149.69Feb 2, 26$141.13Feb 4, 26$134.19Feb 9, 26$117.25Feb 11, 26$116.38Feb 13, 26$116.81Feb 18, 26$120.09Feb 20, 26$117.67Feb 24, 26$122.90Feb 26, 26$127.40Mar 2, 26$132.89Mar 4, 26$128.97Mar 6, 26$124.62Mar 10, 26$122.35Mar 12, 26$115.56Mar 17, 26$120.84Mar 19, 26$126.59Mar 23, 26$123.79Mar 25, 26$126.20Mar 27, 26$117.67Mar 31, 26$123.26Apr 2, 26$127.38Apr 7, 26$126.44Apr 9, 26$123.67Apr 13, 26$126.96Apr 15, 26$132.26Apr 17, 26$134.50Apr 22, 26$130.50Apr 24, 26$127.88Apr 28, 26$126.92Apr 30, 26$126.74May 4, 26$139.37May 6, 26$142.58May 8, 26$141.88May 12, 26$145.70May 14, 26$143.24May 18, 26$141.51May 20, 26$141.92May 22, 26$144.41May 28, 26$158.70Jun 1, 26$164.40Jun 3, 26$170.93Jun 5, 26$162.32Jun 9, 26$160.03Jun 11, 26$166.21Jun 15, 26$166.89Jun 17, 26$159.09Jun 22, 26$161.38Jun 24, 26$175.09Jun 26, 26$176.55Jul 2, 26$188.68
$91.0052-week range$188.68
Loading valuation history…

Fundamentals

Key fundamentals

$25B

Market cap

-0.8%

Revenue growth (YoY)

66.7%

Gross margin

$931M

Free cash flow (USD)

$920M

Net debt

-2.5%

Share dilution

1/4

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$2.4BFY 2017$2.8BFY 2018$3.3BFY 2019$3.5BFY 2021$3.2BFY 2022$4.5BFY 2023$4.6BFY 2024$4.4BFY 2025$4.3B
$2.4B$4.3B

Free cash flow by year

2016 → 2025

FY 2016$415.9MFY 2017$563.0MFY 2018$846.0MFY 2019$842.0MFY 2021$891.0MFY 2022$337.0MFY 2023$106.0MFY 2024$709.0MFY 2025$931.0M
$415.9M$931M

Gross margin by year

2021 → 2025

FY 202168.0%FY 202269.7%FY 202364.8%FY 202465.4%FY 202566.7%
68.0%66.7%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

8

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 4, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $111KDavies Scott M · Chief Legal Officer · $110.7KJun 25, 2026Filing
  • 8-K eventDirector AppointmentJun 23, 2026Filing
  • Insider sellInsider Sell $127KLeckman Patricia · SVP, Chief People Officer · $127.3KJun 9, 2026Filing
  • Insider sellInsider Sell $127KLeckman Patricia · SVP, Chief People Officer · $127.1KJun 4, 2026Filing
  • Insider sellInsider Sell $305KEricksen Scott D · VP, Chief Accounting Officer · $305.2KJun 1, 2026Filing
  • Insider sellInsider Sell $98KDavies Scott M · Chief Legal Officer · $98.4KJun 1, 2026Filing
  • Insider sellInsider Sell $107.0MMeister Keith A. · Director · $107MJun 1, 2026Filing
  • 8-K eventAnnual Meeting ResultsMay 26, 2026Filing
  • Insider sellInsider Sell $47.9MMeister Keith A. · Director · $47.9MMay 14, 2026Filing
  • Insider sellInsider Sell $97KWedel Christensen Jakob · SVP, Strategy/Corp Development · $97.3KMay 7, 2026Filing

Questions

Frequently asked questions

What is Illumina, Inc.'s market cap?

Illumina, Inc. (ILMN) has a market capitalization of $25B.

What is ILMN's P/E ratio?

ILMN trades at a price-to-earnings ratio of 26.2, based on its latest fiscal-year diluted earnings per share and the most recent cached price.

What is ILMN's price-to-book (P/B) ratio?

ILMN trades at 9.17 times book value per share.

Are insiders buying ILMN stock?

SEC Form 4 filings show no open-market insider buys at Illumina, Inc. in the last 90 days (8 sells).

Same arena

Related companies in Medical - Diagnostics & Research

WAT

Waters Corporation

$25B

MTD

Mettler-Toledo International Inc.

$23.8B

DGX

Quest Diagnostics Incorporated

$21.6B

LH

Labcorp Holdings Inc.

$21.5B

IQV

IQVIA Holdings Inc.

$30.5B

NTRA

Natera, Inc.

$31.7B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.